CLDN3

(redirected from claudin-3)

CLDN3

A gene on chromosome 7q11.23 that encodes claudin-3, an integral membrane protein of the claudin family, the members of which form part of the tight junction strands providing a continuous seal around cells and serving as a physical barrier to prevent solutes and water from passing freely into the interstitial space.
 
Molecular pathology
Claudin-3 has a low-affinity receptor for Clostridium perfringens enterotoxin.
References in periodicals archive ?
To analyze the change of tight junction proteins, we examined the expression of ZO-1, occludin and claudin-3 in IPEC-J2 cells which were pretreated with LTA-BS or B.
In the case of pigs, DON showed a negative effect on the expression of TJ proteins of IPEC and its toxicity could involve a down-regulated expression of ZO-1, occludin and claudin-3 of IPEC-J2 (Diesing et al.
Furthermore, our study demonstrated that 24 h treatment with LTA-BS enhanced the expression of tight junction proteins, including ZO-1, occludin and claudin-3 in porcine epithelial cells, and protected against 48 h DON exposure (unpublished data).
Increased amounts of the cell cycle proteins cyclin E and p16, amplification and overexpression of the ERBB2 [v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2] gene (which encodes the ERBB2 receptor tyrosine kinase), loss of BAF250A production, and altered amounts of the cell adhesion proteins claudin-3, claudin-4, L1CAM (L1 cell adhesion molecule), EpCAM (epithelial cell adhesion molecule), and E-cadherin have also been documented [reviewed in (24)].
Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.
Overexpression of claudin-5 but not claudin-3 induces formation of trans-interaction-dependent multilamellar bodies
0813348106) demonstrate that RNAi silencing of the claudin-3 protein using lipidoid formulations of small interfering RNAs (siRNAs, the molecules that mediate RNAi) results in the suppression of ovarian tumor growth and metastases.
Advanced-stage ovarian cancer is extremely difficult to treat with today's medicines, and these new data suggest that an RNAi therapeutic targeting claudin-3 may represent a novel treatment option in the future.
The published data showed that lipidoid-mediated delivery of siRNAs targeting claudin-3 in ovarian tumor tissue resulted in the dramatic silencing of the gene and a substantial reduction in tumor growth and metastases as compared to controls in three different mouse tumor models.
in an ovarian cancer cell xenograft model with intratumoral injection, a significant silencing of claudin-3, a reduction in cell proliferation and tumor growth, and a significant increase in the number of apoptotic cells;
in an ovarian tumor-bearing transgenic mouse model with intraperitoneal dosing, an approximately 40% suppression of tumor growth rate, including tumor regression in some mice, compared to controls, and a significant reduction of malignant ascites (fluid in the abdominal cavity that contains cancer cells), where only 22% of mice treated with the claudin-3 siRNA developed ascites compared to 75% of control-treated animals; and,